The Clinical Usefulness of Prostate Specific Antigen: Update 1994
The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
In conclusion, PSA is the first prostate specific serum marker of clinical usefulness in urology. It represents a valuable clinical tool that has improved our ability to detect early prostate cancer and to monitor response to therapy. While large PSA screening studies have demonstrated an appreciable increase in the detection of organ confined, potentially curable prostate cancers, no study to date has yet demonstrated that the increased detection rate will decrease the prostate cancer-specific mortality rate. Yet more importantly, no study to date has demonstrated that early diagnosis using PSA will not decrease the prostate cancer specific mortality rate and until such data exist, PSA should be used to aid in early diagnosis and treatment planning for men with prostate cancer. PSA, when combined with other variables such as Gleason score and clinical stage, improves the prediction of pathological stage for prostate cancer. The introduction of PSA velocity and age specific reference ranges should further enhance the clinical usefulness of PSA. New advances in PSA research hold great promise for further improvements in PSA, and truly make it the most important and useful tumor marker for adenocarcinoma of the prostate.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prostate-Specific Antigen as a Serum Marker for Adenocarcinoma of the Prostate
Stamey, T. A., Yang, N., Hay, A. R., McNeal, J. E., Freiha, F. S., & Redwine, E. (1987) · New England Journal of Medicine · doi:10.1056/nejm198710083171501 · Cited by 2,451
Measurement of Prostate-Specific Antigen in Serum as a Screening Test for Prostate Cancer
Catalona, W. J., Smith, D. S., Ratliff, T. L., Dodds, K. M., Coplen, D. E., Yuan, J. J. J., Petros, J. A., & Andriole, G. L. (1991) · New England Journal of Medicine · doi:10.1056/nejm199104253241702 · Cited by 2,361
Partin, A. W., Yoo, J., Carter, H. B., Pearson, J. D., Chan, D. W., Epstein, J. I., & Walsh, P. C. (1993) · Journal of Urology · doi:10.1016/s0022-5347(17)35410-1 · Cited by 1,278
Self-citationOesterling, J. E. (1993) · JAMA · doi:10.1001/jama.270.7.860 · Cited by 1,266
Self-citationOesterling, J. E. (1991) · Journal of Urology · doi:10.1016/s0022-5347(17)38491-4 · Cited by 1,230
Self-citationLongitudinal Evaluation of Prostate-Specific Antigen Levels in Men With and Without Prostate Disease
Carter, H. B. (1992) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1992.03480160073037 · Cited by 1,096
Catalona, W. J. (1993) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1993.03510080052031 · Cited by 998
Boring, C. C., Squires, T. S., & Tong, T. (1993) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.43.1.7 · Cited by 966
Stenman, U., Leinonen, J., Alfthan, H. V., et al. (1991) · PubMed · Cited by 930
Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin
Lilja, H., Christensson, A., Dahlén, U., Matikainen, M. T., Nilsson, O., Pettersson, K., & Lövgren, T. (1991) · Clinical Chemistry · doi:10.1093/clinchem/37.9.1618 · Cited by 910
Cited by
Design of the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial
Prorok, P. C., Andriole, G. L., Bresalier, R. S., Buys, S. S., Chia, D., David Crawford, E., Fogel, R., Gelmann, E. P., Gilbert, F., Hasson, M. A., et al. (2000) · Controlled Clinical Trials · doi:10.1016/s0197-2456(00)00098-2 · Cited by 1,037
Imaging Prostate Cancer: A Multidisciplinary Perspective
Hricak, H., Choyke, P. L., Eberhardt, S. C., Leibel, S. A., & Scardino, P. T. (2007) · Radiology · doi:10.1148/radiol.2431030580 · Cited by 601
PROSTATE SPECIFIC ANTIGEN: A DECADE OF DISCOVERY-WHAT WE HAVE LEARNED AND WHERE WE ARE GOING
POLASCIK, T. J., OESTERLING, J. E., & PARTIN, A. W. (1999) · Journal of Urology · doi:10.1016/s0022-5347(05)68543-6 · Cited by 599
Self-citationProstate Specific Antigen Best Practice Statement: 2009 Update
Greene, K. L., Albertsen, P. C., Babaian, R. J., Carter, H. B., Gann, P. H., Han, M., Kuban, D. A., Sartor, A. O., Stanford, J. L., Zietman, A., et al. (2009) · Journal of Urology · doi:10.1016/j.juro.2009.07.093 · Cited by 517
P504S: A New Molecular Marker for the Detection of Prostate Carcinoma
Jiang, Z., Woda, B. A., Rock, K. L., Xu, Y., Savas, L., Khan, A., Pihan, G., Cai, F., Babcook, J. S., Rathanaswami, P., et al. (2001) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200111000-00007 · Cited by 365
Rittenhouse, H. G., Finlay, J. A., Mikolajczyk, S. D., & Partin, A. W. (1998) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408369891234219 · Cited by 303
Self-citationProstate cancer diagnosis and management
Frydenberg, M., Stricker, P. D., & Kaye, K. W. (1997) · The Lancet · doi:10.1016/s0140-6736(96)07393-x · Cited by 281
Prostate-Specific Antigen Values at the Time of Prostate Cancer Diagnosis in African-American Men
Moul, J. W. (1995) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1995.03530160029029 · Cited by 271
Novel diagnostic biomarkers for prostate cancer
Madu, C. O., & Lu, Y. (2010) · Journal of Cancer · doi:10.7150/jca.1.150 · Cited by 261
NONPROSTATIC SOURCES OF PROSTATE-SPECIFIC ANTIGEN
Diamandis, E. P., & Yu, H. (1997) · Urologic Clinics of North America · doi:10.1016/s0094-0143(05)70373-6 · Cited by 172
Metadata
- Authors
- Partin, A. W., & Oesterling, J. E.
- Venue
- Journal of Urology
- Published
- 1994-11
- Volume
- 152
- Issue
- 5 Part 1
- Pages
- 1358-1368
- ISSN
- 0022-5347 (ISSN-L)
- 1527-3792
- OpenAlex
- W127182478
- Cited by
- 390
- References
- 40
- FWCI
- 42.50
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.